The production of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, represents a complex several-stage synthetic process. Initial routes focused on amino acid chain fragment coupling, utilizing solid-phase creation methodologies to build the long amino acid sequence. Subsequent study has explored alternative approaches, incl